ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2014
Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.Annals of hematology · 2020Trial
- A next-generation sequencing-based assay for minimal residual disease assessment in AML patients withBlood advances · 2018Trial
- Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD.Haematologica · 2016Trial
- Ultrasensitive quantitation of FLT3-ITD mutation in patients with acute myeloid leukemia using ddPCR.Molecular biology reports · 2023Article
- Clinical Implications of theCancers · 2023Article
- Article
- Target Therapy for Extramedullary Relapse ofCancers · 2022Review
- A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication.Diagnostic pathology · 2022Article
- Methods and role of minimal residual disease after stem cell transplantation.Bone marrow transplantation · 2019Review
- Review
- Clinical implications of molecular markers in acute myeloid leukemia.European journal of haematology · 2019Review
- The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.Blood reviews · 2017Review
- Haplotype Counting for Sensitive Chimerism Testing: Potential for Early Leukemia Relapse Detection.The Journal of molecular diagnostics : JMD · 2017Article
- Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.American journal of hematology · 2017Article
- Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.British journal of haematology · 2016Article
- Life after transplant: are we becoming high maintenance in AML?Bone marrow transplantation · 2016Review
- Allogeneic transplant for FLT3-ITD+ AML: room for improvement.Bone marrow transplantation · 2016Article
- A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.Molecular diagnosis & therapy · 2015Article
- Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length.Blood cancer journal · 2015Article
- Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Current hematologic malignancy reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Patients with acute myeloid leukemia (AML) who harbor internal tandem duplication (ITD) mutations of the FMS-like tyrosine kinase 3 (FLT3) gene carry a poor prognosis. Although allogeneic transplantation may improve outcomes, relapse occurs frequently. The FLT3/ITD mutation has been deemed an unsuitable minimal residual disease (MRD) marker because it is unstable and because the standard assay for the mutation is relatively insensitive. The FLT3 mutation is undetectable by PCR at pre- or post-transplant time points in many FLT3/ITD AML patients who subsequently relapse after transplant. We report the application of a new technique, tandem duplication PCR (TD-PCR), for detecting MRD in FLT3/ITD AML patients. Between October 2004 and January 2012, 54 FLT3/ITD AML patients in remission underwent transplantation at our institution. Of 37 patients with available day 60 marrow samples, 28 (76%) were assessable for MRD detection. In seven of 28 patients (25%), the FLT3/ITD mutation was detectable by TD-PCR but not by standard PCR on day 60. Six of 7 patients (86%) with MRD by TD-PCR have relapsed to date compared with only 2 of 21 patients (10%) who were negative for MRD (P = .0003). The ability to detect MRD by this sensitive technique may provide an opportunity for early clinical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.